|
|
|
Neurogen Releases Results Clinical Trial for Anxiety Drug
|
Business New Haven
1/21/2002
By: BNH
|
BRANFORD - Neurogen Corp. (NASDAQ: NRGN), a small molecule drug discovery and development company, announced preliminary results from a Phase IIA clinical study of NGD 91-3, the Company's lead drug candidate for the treatment of anxiety disorders. NGD 91-3 is one of several drug candidates that work through selective modulation of the neurotransmitter system known as GABA (gamma aminobutyric acid), which are being developed for treatment of neuropsychiatric disorders in collaboration with Pfizer Inc (NYSE: PFE). The Phase IIA clinical trial conducted by Pfizer was a randomized, double-blind, placebo-controlled evaluation of the safety, pharmacokinetics, and efficacy of NGD 91-3 in patients suffering from generalized anxiety disorder (GAD). Phase II clinical trials are designed to explore the potential efficacy and safety of the drug in a targeted patient population, and to determine drug doses most appropriate for future clinical trials.
|
Go FirstGo PreviousGo
NextGo LastGo
to Index
|
|
